Horse

Clenbuterol

Tissue

MRL

Year of Adoption

Note

Fat

0.2 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Tissue

Fat

MRL

0.2 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Kidney

0.6 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Tissue

Kidney

MRL

0.6 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Liver

0.6 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Tissue

Liver

MRL

0.6 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Muscle

0.2 µg/kg

2003

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Tissue

Muscle

MRL

0.2 µg/kg

Year of Adoption

2003

Note

Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.

Showing 1 to 4 of 4 entries

Dexamethasone

Tissue

MRL

Year of Adoption

Note

Kidney

1.0 µg/kg

2009

None

Tissue

Kidney

MRL

1.0 µg/kg

Year of Adoption

2009

Note

None

Liver

2.0 µg/kg

2009

None

Tissue

Liver

MRL

2.0 µg/kg

Year of Adoption

2009

Note

None

Muscle

1.0 µg/kg

2009

None

Tissue

Muscle

MRL

1.0 µg/kg

Year of Adoption

2009

Note

None

Showing 1 to 3 of 3 entries

Febantel/Fenbendazole/Oxfendazole

Tissue

MRL

Year of Adoption

Note

Fat

100 µg/kg

1999

None

Tissue

Fat

MRL

100 µg/kg

Year of Adoption

1999

Note

None

Kidney

100 µg/kg

1999

None

Tissue

Kidney

MRL

100 µg/kg

Year of Adoption

1999

Note

None

Liver

500 µg/kg

1999

None

Tissue

Liver

MRL

500 µg/kg

Year of Adoption

1999

Note

None

Muscle

100 µg/kg

1999

None

Tissue

Muscle

MRL

100 µg/kg

Year of Adoption

1999

Note

None

Showing 1 to 4 of 4 entries